- Home
- ABTS vs INTS Comparison
ABTS vs INTS Comparison
Compare ABTS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- INTS
- Stock Information
- Founded
- ABTS 2010
- INTS 2012
- Country
- ABTS Hong Kong
- INTS United States
- Employees
- ABTS N/A
- INTS N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- INTS Health Care
- Exchange
- ABTS Nasdaq
- INTS Nasdaq
- Market Cap
- ABTS 8.9M
- INTS 8.4M
- IPO Year
- ABTS N/A
- INTS 2023
- Fundamental
- Price
- ABTS $3.48
- INTS $0.28
- Analyst Decision
- ABTS
- INTS Strong Buy
- Analyst Count
- ABTS 0
- INTS 4
- Target Price
- ABTS N/A
- INTS $4.50
- AVG Volume (30 Days)
- ABTS 8.7K
- INTS 3.8M
- Earning Date
- ABTS 08-13-2025
- INTS 08-07-2025
- Dividend Yield
- ABTS N/A
- INTS N/A
- EPS Growth
- ABTS N/A
- INTS N/A
- EPS
- ABTS N/A
- INTS N/A
- Revenue
- ABTS $7,037,156.00
- INTS N/A
- Revenue This Year
- ABTS N/A
- INTS N/A
- Revenue Next Year
- ABTS N/A
- INTS N/A
- P/E Ratio
- ABTS N/A
- INTS N/A
- Revenue Growth
- ABTS 31.69
- INTS N/A
- 52 Week Low
- ABTS $1.35
- INTS $0.19
- 52 Week High
- ABTS $14.10
- INTS $4.34
- Technical
- Relative Strength Index (RSI)
- ABTS 38.61
- INTS 45.18
- Support Level
- ABTS $3.40
- INTS $0.27
- Resistance Level
- ABTS $3.89
- INTS $0.32
- Average True Range (ATR)
- ABTS 0.25
- INTS 0.02
- MACD
- ABTS -0.03
- INTS -0.00
- Stochastic Oscillator
- ABTS 9.54
- INTS 29.48
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.